Important note: Information in this article was accurate in May 2006. The state of the art may have changed since the publication date.
ARV treatments rapidly reduces cervical and vaginal HIV-1 RNA
HIV Treat Bull - Vol. 7, No. 5, May 2006
Decreased genital HIV-1 RNA shedding in women is associated with lower risk of both mother to child transmission and probably heterosexual transmission. A poster by Susan Graham and coworkers reported findings from an evaluation of genital HIV-1 RNA shedding in women in women initiating antiretroviral therapy.
This study, conducted in Mombassa, Kenya, compared HIV-1 RNA decay rates in blood plasma, cervical and vaginal secretions during the first month of receiving treatment. A group of 20 drug naïve female sex workers participated after initiation of antiretroviral treatment of d4T, 3TC and nevirapine.
Intensive sampling was performed and interviews and examinations were conducted at each visit. Samples were collected on days 0, 2, 7, 14, and 28 for blood plasma and days 0, 1, 2, 4, 7, 14, and 28 for genital swabs. RNA levels at different time points were compared.
The authors reported excellent adherence levels, median 100% (range 98.9 -100%). On day 0, the median blood plasma HIV-1 RNA was 5.4 log copies/mL (IQR, 5.0-5.9 log copies/mL) and CD4 count 120 cells/mm3 (IQR, 58 -161 cells/mm3). All women had genital HIV-1 RNA shedding at baseline, with median 3.7 log10 copies/swab (IQR, 3.0 - 4.5 log copies/swab) in cervical secretions and 3.8 log1 copies/swab (IQR, 3.1 - 4.5 log copies/swab) in vaginal secretions.
They observed significant decreases by day 2 in blood plasma (p<0.001) and in cervical secretions (p = 0.001) and by day 4 in vaginal secretions (p <0.001).
They found the Initial decay rates in blood plasma, cervical, and vaginal compartments were 0.6, 0.8, and 1.2 log virions per day. Subsequent decay rates were 0.04, 0.05, and 0.06 log virions per day, respectively. They also reported a significantly faster initial decay rate for vaginal HIV-1 RNA shedding than for blood plasma (p = 0.02). At day 28, 19 women had detectable HIV-1 RNA in blood plasma (range 2.2-4.3 log copies/mL), 6 in cervical secretions (range, 1.7-3.1 log copies/swab) and 4 in vaginal secretions (range, 2.1-3.1 log copies/swab).
They concluded: “Genital HIV-1 RNA shedding decreased rapidly after ART initiation, but 7 of 20 women had detectable genital HIV-1 shedding after 1 month of ART. These findings are consistent with a rapid decrease in infectivity. However, persistent genital HIV-1 shedding may indicate an ongoing risk of transmission by some women.”
Ref: Graham S, Holte S, Richardson B et al. Initiation of ART leads to a rapid decline in cervical and vaginal HIV-1 RNA. 13th CROI, Denver, 2006. Abstract 130.
2008-03-10
IB060705-17
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.